What Cancer Patients Actually Think About Vaporizing Medical Cannabis for Appetite | Research

The takeaway

Ten out of 12 advanced cancer patients perceived appetite benefits from vaporized cannabis flower, and psychoactive effects were well-tolerated—even enjoyed—though throat irritation was a common complaint.

Cancer patients considering cannabis for appetite loss, palliative care physicians, and carers supporting loved ones with advanced cancer.

What the researchers found

This qualitative study interviewed 10 advanced cancer patients enrolled in a Phase I/IIb clinical trial of vaporized cannabis flower for cancer-related anorexia, along with 6 of their family carers.

All patients perceived benefits to eating, though the mechanism varied. Most described appetite stimulation directly, but two attributed the benefit to reduced nausea rather than increased hunger—an important distinction suggesting cannabis may help with eating through multiple pathways.

The psychoactive effects are particularly noteworthy. Rather than being a problem, patients generally tolerated the "high" well, and some actively enjoyed it. For people with advanced cancer facing existential distress, this isn't surprising—mild euphoria may itself be therapeutic in palliative care. This contrasts with the typical clinical framing of psychoactivity as purely an adverse effect.

An interesting observer effect emerged: carers sometimes perceived more eating benefit than patients themselves did. This could reflect carers' wishful thinking or their ability to notice changes in eating patterns that patients didn't recognize.

The downsides were relatively minor and transient: throat irritation from vaporizing, and complaints about taste and smell. These are practical issues that might steer some patients toward other cannabis formulations (oils, edibles) rather than away from cannabis entirely.

Why it matters

Clinical trials measure outcomes with scales and numbers, but this qualitative work captures what the experience is actually like for patients. The finding that psychoactive effects were welcomed rather than feared challenges assumptions about how cannabis should be dosed in palliative care (many protocols aim to minimize psychoactivity). The carer perspective also matters—family members' perceptions of benefit influence whether patients continue treatment.

The numbers in context

10 of 12 trial participants interviewed, plus 6 carers. All perceived eating benefits. 2 attributed benefit to nausea reduction rather than appetite stimulation. Psychoactive effects well-tolerated. Throat irritation was the main complaint.

How the study worked

Qualitative study using face-to-face semi-structured interviews with 10 of 12 advanced cancer trial participants and 6 carers. Analysis used the framework method. Setting: inpatient specialist palliative care. Patients were enrolled in a Phase I/IIb clinical trial of vaporized medicinal cannabis flower bud.

Who was studied

N=12 adults with advanced cancer and 6 family carers, inpatient palliative care setting

What this study cannot tell us

Very small sample (10 patients, 6 carers) from a single palliative care setting. Qualitative design can't determine whether perceived benefits reflect actual physiological changes. Participants knew they were receiving cannabis (not blinded), which introduces expectation effects. Inpatient setting may not reflect home use experiences.

How to read the evidence

Qualitative interviews from a small Phase I/IIb trial—captures patient experiences but can't establish efficacy or generalizability.

When this study was published

Published in 2025 in the Journal of Palliative Medicine.

The bigger picture

RTHC-00158 tested THC:CBD oil for cancer symptoms in a rigorous RCT and found no overall symptom benefit but specific pain improvement. This qualitative study provides the patient voice that RCTs miss—perceived appetite benefits that may not show up as statistically significant changes in symptom scores but matter to the individual. Together, they suggest cannabis in cancer care may work through mechanisms that standard outcome measures don't fully capture.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Would vaporized flower produce different outcomes than oils or edibles for cancer anorexia? Should psychoactive effects be embraced rather than minimized in palliative care? Does the carer-patient perception gap affect treatment decisions?

Read the original research

Benefits and Burdens of Vaporized Botanical Cannabis Flower Bud for Cancer-Related Anorexia: A Qualitative Study of the Experiences of People with Advanced Cancer Enrolled as Inpatients in a Phase I/IIb Clinical Trial and Their Family Carers.

Journal of palliative medicine, 28(9), 1246-1250

The Journal of Palliative Medicine is a reputable source focusing on care for patients with serious illnesses.

View on PubMed ↗Publisher’s paper ↗

Citation

Luckett, Tim; Razmovski-Naumovski, Valentina; Garcia, Maja; Phillips, Jane; Chye, Richard; Noble, Beverley; Fazekas, Belinda; Martin, Jennifer; Agar, Meera. (2025). Benefits and Burdens of Vaporized Botanical Cannabis Flower Bud for Cancer-Related Anorexia: A Qualitative Study of the Experiences of People with Advanced Cancer Enrolled as Inpatients in a Phase I/IIb Clinical Trial and Their Family Carers.. Journal of palliative medicine, 28(9), 1246-1250. https://doi.org/10.1177/10966218251372439